Clinical application and research progress of 225Ac for tumor targeted therapy
10.3760/cma.j.cn321828-20210721-00243
- VernacularTitle:225Ac用于核素靶向治疗的临床应用及研究进展
- Author:
Jiao MA
1
;
Lei OU
;
Zijuan RAO
;
Taiping LIAO
;
Lanying LI
;
Chunyin ZHANG
Author Information
1. 西南医科大学附属医院核医学科、核医学与分子影像学四川省重点实验室、四川省院士（专家）工作站，泸州 646000
- Keywords:
Radiotherapy;
Actinium;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(1):52-54
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the application of alpha particle-based nuclide targeted therapy in tumors has shown great potential. 225Ac is a nuclide that can be used for alpha radionuclide targeted therapy which has been studied at home and abroad. A number of preclinical and clinical trials have been carried out, and some achievements have been obtained. This article summarizes the current research status of several malignant tumors, and analyzes the challenges and progress faced by 225Ac in radionuclide targeted therapy.
